Media inquiries

media@disarmtx.com
+1.202.930.4762

Publications

SARM1 the Central Driver of Axonal Degeneration

Development of SARM1 Inhibitors to Treat Peripheral Neuropathies
Robert Hughes, Rajesh Devraj, Thomas Engber, Todd Bosanac and Raul Krauss
Presented at the 2018 Peripheral Nerve Society Annual Meeting. 2018 July 23

Sarm1 Deletion, but Not WldS, Confers Lifelong Rescue in a Mouse Model of Severe Axonopathy
Gilley J, Ribchester R, Coleman M.
Cell Rep. 2017 Oct 3;21(1):10-16

The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.
Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J.
Neuron. 2017 Mar 22;93(6):1334-1343

SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.
Summers DW, Gibson DA, DiAntonio A, Milbrandt J.
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6271-E6280

Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.
Gerdts J, Summers DW, Milbrandt J, DiAntonio A.
Neuron. 2016 Feb 3;89(3):449-60

SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J.
Science. 2015 Apr 24;348(6233):453-7

Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons.
Summers DW, DiAntonio A, Milbrandt J.
J Neurosci. 2014 Jul 9;34(28):9338-50

Sarm1-mediated axon degeneration requires both SAM and TIR interactions.
Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J.
J Neurosci. 2013 Aug 14;33(33):13569-80

Measuring Axonal Degeneration

Neurofilaments and 10-year follow-up in multiple sclerosis
Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E
Multiple Sclerosis Journal 2018 Aug 1

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
Giovannoni G, MBBCh, PhD
BRAIN 2018 Aug; 141(8): 2235–2237

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
Sandelius A, Zetterberg H, Blennow K, Adiutori R, Malaspina A, Laura M, Reilly MM, Rossor AM
Neurology 2018;90:e518-e524. doi:10.1212/WNL.0000000000004932

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis
Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ
Lancet Neurol 2017; 16: 601–09

Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H Leppert D, Kappos L, Gobbi, C, Kuhle J, and the Swiss Multiple Sclerosis Cohort Study Group
ANN NEUROL 2017;81:857–870

Blood-based NfL – A biomarker for differential diagnosis of parkinsonian disorder
Hansson O, Janelidze S, Hall S. Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren, Constantinescu R, Zetterberg H, Blennow K
Neurology, February 8, 2017, DOI

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A
Neurology. 2015 Jun 2; 84(22): 2247–225